Direxion Daily S&P Biotech Bull 3X ETF
LABU
32 hedge funds and large institutions have $42.4M invested in Direxion Daily S&P Biotech Bull 3X ETF in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 4 reducing their positions, and 10 closing their positions.
325% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 4
24% more call options, than puts
Call options by funds: $67.5M | Put options by funds: $54.3M
0% more capital invested
Capital invested by funds: $42.4M → $42.4M (+$12.6K)
0.02% less ownership
Funds ownership: 0.22% → 0.2% (-0.02%)
3% less funds holding
Funds holding: 33 → 32 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$5.61M |
| 2 |
Jane Street
New York
|
+$5.33M |
| 3 |
Renaissance Technologies
New York
|
+$3.43M |
| 4 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
+$2.2M |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIM
Bullseye Investment Management
Cincinnati,
Ohio
|
-$1.9M |
| 2 |
CG
Cutler Group
San Francisco,
California
|
-$1.38M |
| 3 |
Squarepoint
New York
|
-$932K |
| 4 |
UMC
United Maritime Capital
New York
|
-$792K |
| 5 |
JC
JBF Capital
Aspen,
Colorado
|
-$720K |
LABU Hedge Fund Activity: Q1 2022 in Review
32 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q1 2022, worth a combined $42.4M — up 0.03% from $42.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of LABU and 9 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 17 added.
The largest buyer was Citadel Advisors, adding an estimated $5.61M. The largest seller was Bullseye Investment Management, exiting entirely with an estimated $1.9M sold.
- 32 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q1 2022, down from 33 in Q4 2021.
- Funds reported $42.4M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q1 2022, up 0.03% quarter-over-quarter.
- 9 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q1 2022 and 10 closed out, a net change of -1 holder.
- The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q1 2022 was Citadel Advisors, an estimated $5.61M added.
- The largest Direxion Daily S&P Biotech Bull 3X ETF seller in Q1 2022 was Bullseye Investment Management, an estimated $1.9M sold.
Based on aggregated 13F filings for Q1 2022.